Heat shock protein 27 protects L929 cells from cisplatin-lnduced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity

Clinical Cancer Research

Volumn 13, Issue 10, 2007, Pages 2855-2864

  Zhang, Yong ^a,c   Shen, Xun ^a,b  

^a INSTITUTE OF BIOPHYSICS   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c QINGDAO AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; CISPLATIN; HEAT SHOCK PROTEIN 27; PROTEIN KINASE B; SYNAPTOPHYSIN; THIOREDOXIN REDUCTASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL STRAIN L 929; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; ENZYME ACTIVATION; HEAT-SHOCK PROTEINS; HELA CELLS; HUMANS; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; THIOREDOXIN REDUCTASE (NADPH);

EID: 34249801769     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2090     Document Type: Article

References (55)

1. Timmer-Bosscha H, Mulder NH, deVries EG. Modulation of cis-diamminedichloroplatinum (II) resistance: a review. Br J Cancer 1992;66:227-38.
2. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-90.
3. Perez RP. Cellular and molecular determinants of cis-platin resistance. Eur J Cancer 1998;34:1535-42.
4. Garrido C, Schmitt E, Candé C, Vahsen N, Parcellier A, Kroemer G. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2003;6:579-84.
5. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res 1999;248:30-43.
6. Mese H, Sasaki A, Nakayama S, et al. Prognostic significance of heat shock protein 27 (HSP27) in patients with oral squamous cell carcinoma. Oncol Rep 2002;9:341-4.
7. Kapranos N, Kominea A, Konstantinopoulos PA, et al. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol 2002;128: 426-32.
8. Arts HJ, Hollema H, Lemstra W, et al. Heat-shock-protein-27 (Hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. lnt J Cancer 1999;84:234-8.
9. Kasimir-Bauer S, Ottinger H, Meusers P, et al. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27, is predictive of the response to induction chemotherapy. Exp Hematol 1998;26:1111-7.
10. Kasimir-Bauer S, Beelen D, Flasshove M, Noppeney R, Seeber S, Scheuten ME. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. Exp Hematol 2002;30:1302-8.
11. Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett 2001;168:173-81.
12. Wang HP, Hanlon JG, Rainbow AJ, Espiritu M, Singh G. Up-regulation of Hsp27 plays a role in the resistance of human colon carcinoma HT29 cells to photooxidative stress. Photochem Photobiol 2002;76: 98-104.
13. Aghdassi A, Phillips P, Dudeja V, et al. Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res 2007;67:616-25.
14. Milicevic ZT, Petkovic MZ, Drndarevic NC, Pavlovic MD, Todorovic VN. Expression of heat shock protein 70 (HSP70) in patients with colorectal adenocarcinoma immunohistochemistry and Western blot analysis. Neoplasma 2007;54:37-45.
15. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;34:1999-2009.
16. Nanbu K, Konishi I, Mandai M, et al. Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Cancer Detect Prev 1998;22: 549-55.
17. Uozaki H, Ishida T, Kakiuchi C, et al. Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract 2000;196: 665-73.
18. Santarosa M, Favaro D, Quaia M, Galligioni E. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer 1997;33:873-7.
19. Nowakowski GS, McCollum AK, Ames MM, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087-93.
20. Verrills NM, Liem NL, Liaw TY, Hood BD, Lock RB, Kavallaris M. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia-an in vivo study. Proteomics 2006;6: 1681-94.
21. Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998;79:468-75.
22. Morino M, Tsuzuki T, Ishikawa Y, et al. Specific expression of HSP27 in human tumor cell lines in vitro. In Vivo 1997;11:179-84.
23. Rashmi R, Kumar S, Karunagaran D. Ectopic expression of Hsp70 confers resistance and silencing its expression sensitizes human colon cancer cells to curcumin-induced apoptosis. Carcinogenesis 2004; 25:179-87.
24. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22: 7265-79.
25. Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep 2004;12:955-65.
26. Kuida K, Boucher DM. Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress. J Exp Biol 2003;206:1107-15.
27. Tibbles LA, Woodgett JR.The stress-activated protein kinase pathways. Cell Mol Life Sci 1999;55: 1230-54.
28. Benhar M, Dalyot I, Engelberg D, Levitzki A. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol 2001;21:6913-26.
29. Mansouri A, Ridgway LD, Korapati AL, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003;278:19245-56.
30. Chen Z, Seimiya H, Naito M, et al. ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene 1999;18:173-80.
31. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 2003;278:23432-40.
32. Schepers H, Geugien M, Van der Toorn M, et al. HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun. Exp Hematol 2005;33:660-70.
33. Dan HC, Jiang K, Coppola D, et al. Phosphatidylinositol-3-OH kinase/AKT and surviving pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 2004;23:706-15.
34. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 2003;63: 7081-8.
35. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
36. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001;61:1862-8.
37. Hill KE, McCollum GW, Burk RF. Determination of thioredoxin reductase activity in rat liver supernatant. Anal Biochem 1997;253:123-5.
38. Watson WH, Pohl J, Montfort WR, et al. Redox potential of human thioredoxin 1 and identification of a s dithiol/disulfide motif. J Biol Chem 2003;278: 33408-15.
39. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999;59: 3077-83.
40. Tong L, Pav S, White DM, et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol 1997;4:311-6.
41. Cara DC, Kaur J, Forster M, McCafferty D-M, Kubes P. Role of p38 mitogen-activated protein kinase in chemokine-induced emigration and chemotaxis in vivo. J Immunol 2001;167:6552-8.
42. Yano H, Nakanishi S, Kimura K, et al. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem 1993;268:25846-56.
43. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 1993;296:297-301.
44. Du L, Smolewski P, Bedner E, Traganos F, Darzynkiewicz Z. Selective protection of mitogenically stimulated human lymphocytes but not leukemic cells from cytosine arabinoside-induced apoptosis by LY294002, a phosphoinositol-3 kinase inhibitor. Int J Oncol 2001;19:811-9.
45. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998;17:2596-606.
46. Garrido C, Ottavi P, Fromentin A, et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 1997; 57:2661-7.
47. Chung YM, Park S, Park JK, Kim Y, Kang Y, Yoo YD. Establishment and characterization of 5-fluorouracil-resistance gastric cancer cells. Cancer Lett 2000;159: 95-101.
48. Wachsberger PR, Landry J, Storck C, et al. Mammalian cells adapted to growth at pH 6.7 have elevated HSP27 levels and are resistant to cisplatin. Int J Hyperthermia 1997;13:251-5; discussion 257-9.
49. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000;92:1564-72.
50. Richards EH, Hickey E, Weber L, Master JR. Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res 1996;56:2446-51.
51. Paul C, Manero F, Gonin S, Kretz-Remy C,Virot S, Arrigo AP. Hsp27 as a negative regulator of cytochrome C release. Mol Cell Biol 2002;22:816-34.
52. Xanthoudakis S, Nicholson DW. Heat-shock proteins as death determinants. Nat Cell Biol 2000;2: E163-5.
53. Mearow KM, Dodge ME, Rahimtula M, Yegappan C. Stress-mediated signaling in PC12 cells-the role of the small heat shock protein, Hsp27, and Akt in protecting cells from heat stress and nerve growth factor withdrawal. J Neurochem 2002;83: 452-62.
54. Charette SJ, Lavoie J, Lambert H, Landry J. Inhibition of Daxx-mediated apoptosis by heat shock protein 27. Mol Cell Biol 2000;20:7602-12.
55. Charette SJ, Landry J. The interaction of HSP27 with Daxx identifies a potential regulatory role of HSP27 in Fas-induced apoptosis. Ann N Y Acad Sci 2000;926:126-31.